INBS Fundamental Analysis - INTELLIGENT BIO SOLUTIONS IN

Fundamental Rating

Taking everything into account, INBS scores 2 out of 10 in our fundamental rating. INBS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. INBS has a bad profitability rating. Also its financial health evaluation is rather negative. INBS has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

INBS had negative earnings in the past year.

INBS had a negative operating cash flow in the past year.

In the past 5 years INBS always reported negative net income.

INBS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -128.11%, INBS is not doing good in the industry: 81.91% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -352.75%, INBS is doing worse than 76.60% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-128.11%
ROE	-352.75%
ROIC	N/A

ROA(3y)-101.5%

ROA(5y)-80.79%

ROE(3y)-251.51%

ROE(5y)-185.33%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 40.85%, INBS is not doing good in the industry: 65.96% of the companies in the same industry are doing better.

INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	40.85%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, INBS has more shares outstanding

Compared to 5 years ago, INBS has more shares outstanding

Compared to 1 year ago, INBS has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -13.90, we must say that INBS is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -13.90, INBS is not doing good in the industry: 81.38% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.07 indicates that INBS is not too dependend on debt financing.

With a decent Debt to Equity ratio value of 0.07, INBS is doing good in the industry, outperforming 68.09% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Altman-Z	-13.9

ROIC/WACCN/A

WACC8.39%

2.3 Liquidity

A Current Ratio of 0.77 indicates that INBS may have some problems paying its short term obligations.

The Current ratio of INBS (0.77) is worse than 92.02% of its industry peers.

A Quick Ratio of 0.65 indicates that INBS may have some problems paying its short term obligations.

The Quick ratio of INBS (0.65) is worse than 90.43% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.77
Quick Ratio	0.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.76%, which is quite impressive.

INBS shows a decrease in Revenue. In the last year, the revenue decreased by -1.90%.

Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 74.49% on average per year.

EPS 1Y (TTM)94.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%51.79%

Revenue 1Y (TTM)-1.9%

Revenue growth 3Y91.13%

Revenue growth 5Y74.49%

Sales Q2Q%15.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y128%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year126.26%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

INBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 1.88, the valuation of INBS can be described as very cheap.

100.00% of the companies in the same industry are more expensive than INBS, based on the Price/Forward Earnings ratio.

INBS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.12.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	1.88

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

INBS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (11/26/2025, 8:00:02 PM)

After market: 0.6799 +0.01 (+1.37%)

0.6707

+0.01 (+1.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Inst Owners7.94%

Inst Owner Change57.95%

Ins Owners0.6%

Ins Owner Change0%

Market Cap6.09M

Revenue(TTM)3.05M

Net Income(TTM)-10.57M

Analysts85.71

Price TargetN/A

Short Float %9.22%

Short Ratio2.43

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-79.63%

Min Revenue beat(2)-80.72%

Max Revenue beat(2)-78.54%

Revenue beat(4)0

Avg Revenue beat(4)-70.98%

Min Revenue beat(4)-80.72%

Max Revenue beat(4)-51.15%

Revenue beat(8)0

Avg Revenue beat(8)-51.21%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	1.88
P/S	2
P/FCF	N/A
P/OCF	N/A
P/B	2.03
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2.08

EYN/A

EPS(NY)0.36

Fwd EY53.23%

FCF(TTM)-1.09

FCFYN/A

OCF(TTM)-1.07

OCFYN/A

SpS0.34

BVpS0.33

TBVpS-0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-128.11%
ROE	-352.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	40.85%
FCFM	N/A

ROA(3y)-101.5%

ROA(5y)-80.79%

ROE(3y)-251.51%

ROE(5y)-185.33%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.37

Health

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	23.89%
Cap/Sales	7.59%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.77
Quick Ratio	0.65
Altman-Z	-13.9

F-Score3

WACC8.39%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)94.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%51.79%

EPS Next Y128%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-1.9%

Revenue growth 3Y91.13%

Revenue growth 5Y74.49%

Sales Q2Q%15.92%

Revenue Next Year126.26%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-1.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-3.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.1%

OCF growth 3YN/A

OCF growth 5YN/A

INTELLIGENT BIO SOLUTIONS IN / INBS FAQ

Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?

ChartMill assigns a fundamental rating of 2 / 10 to INBS.

What is the valuation status for INBS stock?

ChartMill assigns a valuation rating of 4 / 10 to INTELLIGENT BIO SOLUTIONS IN (INBS). This can be considered as Fairly Valued.

How profitable is INTELLIGENT BIO SOLUTIONS IN (INBS) stock?

INTELLIGENT BIO SOLUTIONS IN (INBS) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for INBS stock?

The Earnings per Share (EPS) of INTELLIGENT BIO SOLUTIONS IN (INBS) is expected to grow by 128% in the next year.

INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INTELLIGENT BIO SOLUTIONS IN / INBS FAQ

Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?

What is the valuation status for INBS stock?

How profitable is INTELLIGENT BIO SOLUTIONS IN (INBS) stock?

Can you provide the expected EPS growth for INBS stock?